hospitals
pharmaceuticals
elite sports
Abingdon, United Kingdom, July 26, 2005 - Toumaz Technology Ltd today announces that its joint venture with Advance Nanotech, Bio-Nano Sensium Technologies, has developed a board level demonstrator of the Bio-Nano Sensium (BNS), an ultra-lower power wireless monitoring system with the potential to revolutionise healthcare management. The demonstrator system is now available to potential customers and partners for evaluation.
The BNS system is based on Toumaz Technology's ground-breaking low-cost, disposable sensor interface chip - the Sensium - that, due to its ultra low power and very small battery size, can be implanted in or worn on the body with complete freedom of movement, unlike existing bulky monitoring solutions. The Sensium is compatible with a wide range of sensors and can be configured to detect vital signs such as ECG, blood oxygen and glucose, body temperature, and even motion and mobility. With the ability to wirelessly transmit "problem" event data to network nodes, these locally intelligent sensor interface devices herald a new area in the monitoring and treatment of chronic conditions, promising improved quality of life for patients.
The demonstration board incorporates the Toumaz ultra-low power wireless platform and Nanopower Sensor Protocol (NSP) operating system, sensor inputs and drivers, and leverages AMxT technology principles to produce a flexible and reconfigurable interface, a micro-controller, a USB interface, and a Graphical User Interface (GUI) for easy set up and programming. For prospective customers, the board level prototype offers the opportunity to evaluate a working model of the BNS system. For partners and system integrators, the demonstrator provides a working platform for obtaining configuration data, developing control and calibration algorithms for bio-nano sensors, and optimising the NSP wireless operating protocol for specific applications. Trials of the single chip BNS system are planned for the second quarter of 2006.
Commenting on today's announcement, Toumaz Technology CEO Keith Errey said, "With this first major hardware deliverable from the Bio-Nano Sensium Technologies program we are able to demonstrate the real potential of the Bio-Nano Sensium to deliver a new paradigm in healthcare. We look forward to collaborating with potential partners as we advance towards full prototype, which will integrate all these functions within an ultra-low power, single chip structure."
Bio-Nano Sensium Technologies is a joint venture between Toumaz Technology and Advance Nanotech, Inc., formed to create bio-nano sensors that can be implanted within the body to diagnose and treat a wide variety of medical conditions. The development effort will focus on the information and communication technology systems necessary for these sensors to interact with their surrounding environment.
The Bio-Nano Sensium will be capable of power consumption orders of a magnitude lower than current state-of-the-art microprocessors. This nano-power mode of operation is vital to the longer lifetimes, reliability, and stability required in biosensors, especially those that are implanted within the body. The Bio-Nano Sensium will be based on industry-standard Complementary Metal Oxide Semiconductor (CMOS) technology so that not only will it have superior functional features to other devices but also be capable of low-cost production.
-- ends -
About Toumaz Technology Ltd.
Toumaz Technology Limited is a developer of advanced RF, analogue and mixed signal semiconductors. The focus of the business is low power devices based on the company's proprietary AMxT (Advanced Mixed Signal) technology which addresses the needs of lower power consumption for mobile and wirelessly connected systems.
About Advance Nanotech, Inc.
Advance Nanotech Inc. is dedicated to ensuring nanotechnology discoveries reach maximum market potential through successful commercialization. Advance is the trusted guide to commercial success for nanotech entrepreneurs spanning the globe, partnering with leading universities to provide scientists and researchers with mission critical infrastructure support to transform their discoveries to marketable solutions. The organization provides a range of services and support including financing, leadership assets and counsel on intellectual property, licensing and regulatory issues. With a portfolio of nearly 20 companies developing technologies which offer potentially breakthrough nanotechnology discoveries in the electronics, biopharma and materials sectors, Advance's goal is to transform the potential for nanotechnology discoveries into innovative products that further evolve existing industries and enable new markets.
care
latest news
Upcoming event
Toumaz CEO Prof. Chris Toumazou To Speak At The Future World Symposium 2010
Upcoming event
Toumaz CTO Dr Alison Burdett To Address Mobile Healthcare Industry Summit
Upcoming event
Toumaz CEO To Be Keynote Speaker at Wireless Health 2010